Clik here to view.
Neovasc upsizes offering due to market interest
Due to market interest, Neovasc (NASDAQ:NVCN; TSX:NVC) has increased the size of its previously announced public offering to 10.5 million common shares from eight million shares at a price of $7.19...
View ArticleClik here to view.
NEJM publishes Neovasc Reducer study
The New England Journal of Medicine has published final results of Neovasc’s (NASDAQ:NVCN; TSX:NVC) COSIRA study assessing the efficacy and safety of the Neovasc Reducer for treatment of refractory...
View ArticleClik here to view.
Neovasc launching Reducer in Europe for RA
Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular...
View ArticleClik here to view.
Leerink starts Neovasc at outperform
Leerink Partners has launched coverage of Neovasc (NASDAQ:NVCN) with an “outperform” rating and $25 price target. The stock closed at $9.20 on Thursday. “Though still early in development, we believe...
View ArticleClik here to view.
Canaccord starts Neovasc at buy
Canaccord Genuity has launched coverage of Neovasc (NASDAQ:NVCN; TSX:NVC) with a “buy” rating and 12-month target price of $15. The stock closed at $8.99 on Wednesday. Neovasc is one of the early...
View Article
